| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454704 | Lung Cancer | 2016 | 4 Pages |
Abstract
We report a case of crizotinib effectiveness in a heavily pretreated patient with a metastatic NSCLC initially considered IHC-positive and FISH-negative for ALK rearrangement. After repeated analyses of tumor samples, borderline ALK FISH-positivity (18.5% positive cells) was demonstrated.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A. Rosoux, P. Pauwels, F. Duplaquet, N. D'Haene, B. Weynand, M. Delos, R. Menon, L.C. Heukamp, E. Thunnissen, S. Ocak,